We therefore used a selection of highly selective and potent kinase inhibitors targeting relevant genetic aberrations along these pathways in bladder cancer cell lines: FGFRi (AZD4547), PI3Kβ/δi (AZD8186), AKTi (AZD5363) and mTORi (AZD2014); and assayed cell death over 5 days.22, 23, 24, 25 Data relating to RT112, which express constitutively active FGFR3 (FGFR3-TACC3), are shown in Figure 1 and used throughout this study to represent our major findings.26 RT112 cultures showed marked sensitivity to both FGFRi and mTORi, but tolerated AKTi and PI3Kβi (Figure 1a). The gene discussed is FGFR3; the disease is urinary bladder carcinoma.